The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...
Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback